Identification of a transcriptional unit adjacent to the breakpoint in the 14;19 translocation of chronic lymphocytic leukemia

Translocation (14;19) in acute biphenotypic leukemia

Translocation (14;19)(q32;q13.1) is an acquired chromosomal rearrangement that has been associated with chronic lymphocytic leukemia of B-cell phenotype frequently progressing to lymphoma. Molecular analysis suggests that the translocation involves the immunoglobulin heavy chain gene on chromosome 14 and the BCL3 oncogene on chromosome 19. We present the first case of t(14;19) in a patient with acute leukemia. Correlation of detailed cytogenetic and molecular genetic studies, cell surface marker analysis, cytochemistry, and electron microscopy indicated that the leukemic cells were biophenotypic, with characteristics consistent with both myeloid and B-lineage lymphoid differentiation.

Altered gene expression and oncogenesis of B-cell neoplasia

B-cell malignancies reveal a number of consistent translocations involving the C-MYC, BCL and IG genes. In common, these rearrangements usually lead to an inability of the involved B-cells to respond to normal regulatory controls for expression of the genes. This usually lead to over-production of the protein products of the genes at inappropriate times of the cell growth cycle and appears to allow a survival advantage to the B-cell. The result of these changes almost certainly plays a prominent role in the development of B-cell neoplasia. Classification of these lymphoma's at a molecular level may be of benefit to determine the prognosis and treatment in addition to providing a useful marker of disease. Determining the molecular basis of these B-cell lymphomas may help our understanding of their pathogenesis. This in turn could lead to more rational treatment aimed at altering the abnormal molecular changes and returning the neoplastic cells to normal cell development.

Ionising radiations from nuclear establishments and childhood leukaemias--an enigma

The Gardner report, recently published in the UK, showing a correlation between incidence of childhood leukaemia and paternal exposure to ionising radiations (amongst fathers working in nuclear power plants) has added a new element to debates about both the risk factors in nuclear power plants and the relationships between ionising radiations and leukaemogenesis. The epidemiologic and genetic evidence concerning leukaemias is reviewed here and it is concluded that the leukaemogenic agent, whose existence is indicated in the Gardner report, is unlikely to be paternal radiation dose per se but rather exposure to another factor that is correlated with parternal radiation dose received.